GCP
NTLA icon

Gill Capital Partners’s Intellia Therapeutics NTLA Stock Holding History

Gill Capital Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$128 Buy
+10
New +$127 ﹤0.01% 671

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Gill Capital Partners's NTLA Position: Q1 2026 in Review

Gill Capital Partners opened a new position in Intellia Therapeutics (NTLA) in Q1 2026: 10 shares worth $128. The stake represents ﹤0.01% of the portfolio and ranks #671 among its holdings.

302 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Gill Capital Partners held 10 shares of Intellia Therapeutics worth $128 as of Q1 2026.
  • Intellia Therapeutics was a new Gill Capital Partners position in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Gill Capital Partners's portfolio in Q1 2026, its #671 holding.
  • 302 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Gill Capital Partners's 13F filing for Q1 2026, filed 13 Apr 2026.